Nishioka Akihito, Ogawa Yasuhiro, Miyatake Kana, Tadokoro Michiko, Nogami Munenobu, Hamada Norihiko, Kubota Kei, Kariya Shinnji, Kohsaki Takuhiro, Saibara Toshiji, Okabayashi Takehiro, Hanazaki Kazuhiro
Department of Diagnostic Radiology and Radiation Oncology, Kochi University School of Medicine, Kohasu, Okoh-cho, Nankoku-shi, Kochi 783-8505, Japan.
Department of First Internal Medicine, Kochi University School of Medicine, Kohasu, Okoh-cho, Nankoku-shi, Kochi 783-8505, Japan.
Oncol Lett. 2014 Jul;8(1):404-408. doi: 10.3892/ol.2014.2101. Epub 2014 Apr 28.
A novel radiosensitization treatment involving the injection of hydrogen peroxide and sodium hyaluronate, using ultrasonic guidance, into a tumor immediately prior to intraoperative radiotherapy (IORT) was established for patients with stage IVa locally advanced unresectable pancreatic cancer. The aim of the present study was to assess the safety and efficacy of this novel treatment, termed Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas-IORT (KORTUC and IORT). In total, 12 patients were treated with KORTUC-IORT, external-beam radiotherapy and systemic chemotherapy using gemcitabine hydrochloride and S-1. For evaluation of the therapeutic and adverse effects, contrast-enhanced computed tomography was conducted prior to the treatment, and one and six months following KORTUC-IORT. Medical examinations were performed every month at the regularly scheduled follow-up visits. The one- and two-year survival rates were 75 and 25%, respectively, and the median survival time was 16 months. All treatments associated with KORTUC-IORT were well-tolerated by the patients, with a small number of adverse effects and no serious complications. It was identified that the delivery of KORTUC-IORT is safe and effective, in combination with external-beam radiotherapy and systemic chemotherapy, for patients with locally advanced unresectable pancreatic cancer.
对于局部晚期不可切除的IVa期胰腺癌患者，建立了一种新的放射增敏治疗方法，即在术中放疗（IORT）前，在超声引导下将过氧化氢和透明质酸钠注入肿瘤内。本研究的目的是评估这种名为高知过氧化氢-不可切除癌放射治疗-IORT（KORTUC-IORT）的新治疗方法的安全性和有效性。共有12例患者接受了KORTUC-IORT、外照射放疗以及使用盐酸吉西他滨和S-1的全身化疗。为评估治疗效果和不良反应，在治疗前以及KORTUC-IORT后1个月和6个月进行了对比增强计算机断层扫描。在定期随访时每月进行体格检查。1年和2年生存率分别为75%和25%，中位生存时间为16个月。患者对与KORTUC-IORT相关的所有治疗耐受性良好，不良反应较少，无严重并发症。结果表明，对于局部晚期不可切除的胰腺癌患者，KORTUC-IORT联合外照射放疗和全身化疗是安全有效的。
